Overview

Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple dosing Solanezumab in subjects with mild-to-moderate AD in Japanese population.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company